NASDAQ:INMD • IL0011595993
The current stock price of INMD is 13.56 USD. Today INMD is down by -0.29%. In the past month the price decreased by -14.72%. In the past year, price decreased by -28.71%.
ChartMill assigns a technical rating of 0 / 10 to INMD. When comparing the yearly performance of all stocks, INMD is a bad performer in the overall market: 83.66% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to INMD. INMD gets an excellent profitability rating and is at the same time showing great financial health properties.
On February 10, 2026 INMD reported an EPS of 0.46 and a revenue of 103.85M. The company beat EPS expectations (8.04% surprise) and missed revenue expectations (-2.48% surprise).
14 analysts have analysed INMD and the average price target is 17.14 USD. This implies a price increase of 26.37% is expected in the next year compared to the current price of 13.56.
For the next year, analysts expect an EPS growth of 3.73% and a revenue growth 1.75% for INMD
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.62. The EPS decreased by -8.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.33% | ||
| ROA | 12.24% | ||
| ROE | 13.73% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.7 | 197.553B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.03 | 176.649B | ||
| SYK | STRYKER CORP | 25.26 | 147.075B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.62 | 109.521B | ||
| IDXX | IDEXX LABORATORIES INC | 43.78 | 50.748B | ||
| BDX | BECTON DICKINSON AND CO | 10.88 | 49.634B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.66 | 49.488B | ||
| RMD | RESMED INC | 21.1 | 37.626B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.73 | 35.608B | ||
| DXCM | DEXCOM INC | 28.87 | 28.503B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.18 | 19.416B | ||
| PODD | INSULET CORP | 38.31 | 17.013B | ||
| HOLX | HOLOGIC INC | 15.04 | 16.846B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 599
Phone: 97249097470
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
The current stock price of INMD is 13.56 USD. The price decreased by -0.29% in the last trading session.
INMD does not pay a dividend.
INMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
14 analysts have analysed INMD and the average price target is 17.14 USD. This implies a price increase of 26.37% is expected in the next year compared to the current price of 13.56.
The Revenue of INMODE LTD (INMD) is expected to grow by 1.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
INMODE LTD (INMD) currently has 599 employees.